| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Dexpropranolol hydrochloride acts as a non-selective beta-adrenergic receptor antagonist, blocking the binding of endogenous catecholamines to beta-1 and beta-2 adrenergic receptors. This leads to a decrease in heart rate, cardiac output, and blood pressure. It also has membrane-stabilizing activity.
|
|---|---|
| ln Vitro |
In vitro, dexpropranolol hydrochloride binds to beta-adrenergic receptors with lower affinity than the levo (L-) enantiomer. It is used to study the stereospecificity of beta-adrenergic receptor binding and the effects of beta-blockade.
|
| ln Vivo |
When administered to cats under halothane anesthesia, the propranolol hydrochloride dyad completely avoided concomitant causal arrhythmias; nevertheless, the mean dosage of (-)-propranolol hydrochloride was 0.09 mg/kg. In anesthetized cats and dogs, the mean dose of navolol was 0.09 mg/kg, and the mean dose of (+)-propranolol hydrochloride was also 0.09 mg/kg. Both forms of propranolol hydrochloride corrected ouabain-induced ventricular tachycardia. In both species, the dose of (-)-propranolol hydrochloride was 4.2 mg/kg, which was much less than the (+) dose [1]. (R)-propranolol hydrochloride [1] is the compound in question. The anti-poppy drug (R)-propranolol hydrochloride (10 mg/kg) may suppress the cardiac response to cumene to a considerably lesser extent than the (-) body in this contact (1 /100)[1].
In vivo, dexpropranolol hydrochloride has beta-blocking activity, but its potency is lower than that of propranolol. It is used in research to study the stereospecificity of beta-adrenergic receptor-mediated effects. |
| Enzyme Assay |
In vitro receptor binding assays for dexpropranolol hydrochloride typically measure its affinity for beta-1 and beta-2 adrenergic receptors. Radiolabeled ligands are displaced by increasing concentrations of the compound to determine binding affinity. Functional assays measure the compound's ability to inhibit beta-adrenergic receptor-mediated signaling.
|
| Cell Assay |
Cell-based assays for dexpropranolol hydrochloride involve treating cells expressing beta-adrenergic receptors with the compound and measuring its effects on receptor-mediated signaling. The compound's ability to inhibit cAMP production is assessed.
|
| Animal Protocol |
In vivo animal studies for dexpropranolol hydrochloride are conducted in models of cardiovascular disease. The compound is administered, and its effects on heart rate, blood pressure, and cardiac function are assessed.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Dextroproprolol (propranolol) has known metabolites including 5-hydroxypropranolol, N-deisopropylpropranolol, and 4-hydroxypropranolol. Dexpropranolol hydrochloride has a molecular weight of 295.80 and a molecular formula of C16H22ClNO2. It is soluble in water and DMSO. For storage, it should be kept at -20°C. |
| Toxicity/Toxicokinetics |
Dexpropranolol hydrochloride is generally well-tolerated. Common side effects include bradycardia, hypotension, and fatigue. It is contraindicated in patients with asthma, heart block, and cardiogenic shock.
|
| References | |
| Additional Infomation |
(R)-(+)-Propranolol is a type of propranolol. Propranolol is a widely used non-selective β-adrenergic antagonist. It was previously used to treat myocardial infarction, arrhythmias, angina pectoris, hypertension, hyperthyroidism, migraines, pheochromocytoma, and anxiety, but due to its adverse effects, it has been superseded by newer medications.
Dexpropranolol hydrochloride is the dextro enantiomer of propranolol, a non-selective beta-adrenergic receptor antagonist. It is used in research to study the stereospecificity of beta-adrenergic receptor binding and the effects of beta-blockade. It is a valuable research tool for studying adrenergic receptor pharmacology. |
| Molecular Formula |
C16H21NO2.HCL
|
|---|---|
| Molecular Weight |
295.80438
|
| Exact Mass |
295.134
|
| CAS # |
13071-11-9
|
| Related CAS # |
5051-22-9;13071-11-9 (HCl);
|
| PubChem CID |
21138
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
434.9ºC at 760 mmHg
|
| Melting Point |
196-198 °C(lit.)
|
| Flash Point |
216.8ºC
|
| Vapour Pressure |
2.48E-08mmHg at 25°C
|
| LogP |
3.77
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
19
|
| Complexity |
257
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O
|
| InChi Key |
AQHHHDLHHXJYJD-CQSZACIVSA-N
|
| InChi Code |
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1
|
| Chemical Name |
(2R)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~845.17 mM)
H2O : ~7.14 mg/mL (~24.14 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (33.81 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3807 mL | 16.9033 mL | 33.8066 mL | |
| 5 mM | 0.6761 mL | 3.3807 mL | 6.7613 mL | |
| 10 mM | 0.3381 mL | 1.6903 mL | 3.3807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
